<DOC>
	<DOCNO>NCT00865137</DOCNO>
	<brief_summary>The purpose study evaluate effect food oral bioavailability tacrolimus modify release ( MR4 ) capsule together standard continental breakfast . The objective ass pharmacokinetics relative bioavailability without food .</brief_summary>
	<brief_title>An Open Study Assessing Bioavailability Modified Formulation Tacrolimus Kidney Transplant Recipients</brief_title>
	<detailed_description>Stable kidney transplant recipient participate clinical trial FG-506-14-02 currently treat FK506E ( MR4 ) fast condition change medication least seven day enrol sub-study . Following enrolment , patient remain medication dose regimen throughout study.During study two 24 hour blood concentration time profile collect , one last day Period 2 Period 3 sub-study follow : Profile 1 Day 7 fast condition Profile 2 Day 14 non-fasted condition A total five schedule visit plan . At least 24 patient two complete , evaluable profile need estimate effect food oral bioavailability FK506E ( MR4 ) . Blood sample - For sample 2 mL aliquot whole blood collect . The total blood volume two profile take per patient approximately 40 mL .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Stable kidney transplant patient age ≥ 18 year participate clinical trial FG5061402 treat FK506E ( MR4 ) The total daily dose immunosuppressive medication , include FK506E ( MR4 ) , concomitant medication remain unchanged least seven day prior enrolment Patient serum creatinine level &lt; 265 μmol/L enrolment Female patient childbearing potential must negative serum urine pregnancy test prior enrolment must agree practice effective birth control study Patient previously receive organ transplant kidney Patient form substance abuse , psychiatric disorder condition may complicate communication investigator Patient experience rejection episode within 90 day prior enrolment , rejection episode within last six month require antilymphocyte antibody therapy two rejection episode within last 12 month Patient chronic dysfunction kidney Patient major change her/his immunosuppressive regimen within last three month prior enrolment Patient significant liver disease , define elevated SGPT/ALT and/or SGOT/AST and/or total bilirubin level ( least two time upper value normal range investigational site ) 28 day prior enrolment Patient receive insulin therapy Patient require treatment medication substance know interfere tacrolimus metabolism take medication within 28 day prior enrolment participation Patient unstable medical condition could interfere study Patient pregnant breastfeed mother Patient know positive HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Tacrolimus modify release</keyword>
	<keyword>FK506E</keyword>
</DOC>